Back to News
Market Impact: 0.35
Haemonetics Q2 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsHealthcare & Biotech
Haemonetics raised its fiscal 2027 revenue growth outlook after posting double-digit organic growth in the second quarter. It lowered its operating margin expansion forecast as it invests to support an expanded relationship with plasma collector CSL.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
HAE0.35
More News
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Decisive election. Dramatic stock swings. How we handled the market last week
- Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline
- Berkshire shares surge as Wall Street swoons amid AI fears
- Paraguay’s ousted president charged over banking scandal
- CoreWeave seeks truce with Texas Governor-elect Hinojosa